Evidence map›Paper›PMID 42903166›Full record

ArticleFrontiers in immunology2026

TREM2

Chi Young Kim, Yoon Jin Cha, Min Kyung Park, Yoon Soo Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chi Young Kim *Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Yoon Jin Cha *Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Min Kyung ParkDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Yoon Soo ChangDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Osimertinib and cisplatin are widely used as standard treatments for non-small cell lung cancer (NSCLC); however, their effects on tumor microenvironment remodeling remain poorly understood. This study investigated whether TREM2-positive tumor-associated macrophages (TAMs) promote immune evasion through the CCL5/CCL22-CCR5/CCR4-Treg axis under anticancer treatment. Methods: The spatial and quantitative correlations between TREM2 Results: scRNA-seq dataset analysis showed significantly enriched TREM2 Conclusion: These findings indicate that TREM2

Indexed as

Adenocarcinoma of LungLung NeoplasmsMacrophagesMembrane GlycoproteinsReceptors, ImmunologicT-Lymphocytes, RegulatoryTumor-Associated MacrophagesAnimalsAntineoplastic AgentsChemokine CCL22Chemokine CCL5FemaleHumansMiceMice, Inbred C57BLSignal TransductionAntineoplastic AgentsCCL22 protein, humanCCL5 protein, humanChemokine CCL22Chemokine CCL5Membrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humananticancer therapycisplatinlung adenocarcinomaosimertinibregulatory T cellssingle-cell RNA sequencingTREM2tumor-associated macrophages

Identifiers

PMID42903166
PMCPMC13680435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.